Connect with us
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

News

Cohen Milstein Sellers & Toll PLLC Announces Investigation of Apyx Medical Corp.

gbafNews28

Cohen Milstein Sellers & Toll PLLC is conducting an investigation to determine whether Apyx Medical Corporation (Apyx or the Company) and certain of its officers and directors made false and misleading statements and/or omissions in violation of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

A class action lawsuit was filed in the U.S. District Court for the Middle District of Florida by another law firm on behalf of purchasers of the common stock of Apyx (NASDAQ: APYX) between August 1, 2018 and April 1, 2019, inclusive (the Class Period).

Apyx developed J-Plasma, a plasma-based surgical product, for cutting, coagulation, and ablation of soft tissue. Apyx markets and sells J-Plasm under the brand name Renuvion Cosmetic Technology. The claims in this case followed Apyxs withdrawal of a 501(k) submission to the FDA for a new indication to market and sell Renuvion for dermal resurfacing procedures.

The complaint alleges that Apyx and certain of its officers and directors (Defendants) misrepresented and/or failed to disclose that: (1) the clinical study on the use of J-Plasma for dermal resurfacing had not met its primary efficacy endpoint; (2) as a result, the IDE clinical study re the same did not support the Companys application for regulatory clearance; (3) as a result, the Company was unlikely to receive regulatory approval of J-Plasma for dermal resurfacing; and (4) as a result of the foregoing, Defendants positive statements about the Companys business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

On April 1, 2019, Apyx announced it had withdrawn its 501(k) submission as the result of concerns raised by the FDA. Apyx further revealed that its IDE trial did not meet its primary endpoint. The price of Apyx shares fell from $6.95 on April 1, 2019 to $4.46 on April 2, 2019.

Cohen Milstein encourages all investors who purchased Apyx common stock between August 1, 2018 and April 1, 2019, or former employees with information concerning this matter to contact the firm.

If you are an Apyx shareholder and would like to discuss your right to recover for your economic loss, you may, without any cost or obligation, call Cohen Milsteins Managing Partner, Steven J. Toll at (888) 240-0775 or (202) 408-4600, or email him at stoll@cohenmilstein.com. If you wish to serve as lead plaintiff, you must move the Court no later than June 17 to request appointment. Any member of the proposed class may retain Cohen Milstein or other attorneys to serve as your counsel in this action, or you may do nothing and remain an absent class member.

Cohen Milstein has significant experience in prosecuting investor class actions and actions involving securities fraud and is active in major litigation pending in federal and state courts throughout the nation. Cohen Milstein has taken a lead role in numerous important cases on behalf of defrauded investors and has been responsible for a number of outstanding recoveries which, in the aggregate, total billions of dollars. Prior results do not guarantee a similar outcome. For more information visit www.cohenmilstein.com.

If you have any questions about this notice or the action, or with regard to your rights, please contact either of the following:

Steven J. Toll, Esq. Marie Mullins Cohen Milstein Sellers & Toll PLLC 1100 New York Avenue, N.W. Fifth Floor Washington, D.C. 20005 Telephone: (888) 240-0775 or (202) 408-4600 Email: stoll@cohenmilstein.com; mmullins@cohenmilstein.com

Attorney Advertising

Steven
J. Toll, Esq.

Marie Mullins
Cohen Milstein Sellers & Toll
PLLC
1100 New York Avenue, N.W.
Fifth Floor
Washington,
D.C. 20005
Telephone: (888) 240-0775 or (202) 408-4600
Email: stoll@cohenmilstein.com;
mmullins@cohenmilstein.com

Advertisement
Editorial & Advertiser disclosure

Call for Entries

Global Banking and Finance Review Awards Nominations 2022
2022 Awards now open. Click Here to Nominate

Newsletters with Secrets & Analysis. Subscribe Now

Recommended

Global Banking & Finance Review® is a leading financial portal and Print Magazine offering News, Analysis, Opinion, Reviews, Interviews & Videos from the world of Banking, Finance, Business, Trading, Technology, Investing, Brokerage, Foreign Exchange, Tax & Legal, Islamic Finance, Asset & Wealth Management. Copyright © 2010-2021 GBAF Publications Ltd - All Rights Reserved.